This study was carried out to compare concentrations of osteopontin (OPN) and osteoprotegerin (OPG) in peripheral arterial disease (PAD). The study population consisted of 200 consecutive subjects in whom both OPN/OPG and ankle–brachial index were measured. It was found that OPN levels, but not OPG levels, were significantly more increased in patients with PAD than those without PAD. Serum OPN levels were significantly lower in subjects with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers than those without these agents. In this study, it has been demonstrated for the first time that serum OPN levels are related to PAD. Inhibition of renin—angiotensin system could decrease OPN levels and prevent the progression of PAD.
MinorettiP., FalconeC., CalcagninoM.Prognostic significance of plasma osteopontin levels in patients with chronic stable angina.Eur Heart J.2006; 27: 802–807.
3.
IsodaK., NishikawaK., KamezawaY.Osteopontin plays an important role in the development of medial thickening and neointimal formation.Circ Res.2002; 91: 77–82.
4.
BruemmerD., CollinsA.R., NohG.Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice.J Clin Invest.2003; 112: 1318–1331.
5.
DenhardtD.T., NodaM., O'ReganA.W., PavlinD., BermanJ.S.Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.J Clin Invest.2001; 107: 1055–1061.
6.
SteitzS.A., SpeerM.Y., McKeeM.D.Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification.Am J Pathol.2002; 161: 2035–2046.
7.
GiachelliC.M., BaseN., AlmeidaM., DenhardtD.T., AlpersC.E., SchwartzS.M.Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques.J Clin Invest.1993; 92: 1686–1696.
8.
PandaD., KunduG.C., LeeB.I.Potential roles of osteopontin and αvβ3 integrin in the development of coronary artery restenosis after angioplasty.Proc Natl Acad Sci U S A.1997; 94: 9308–9313.
9.
GolledgeJ., McCannM., ManganS., LamA., KaranM.Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis.Stroke.2004; 35: 1636–1641.
10.
ZhangJ., FuM., MylesD.PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways.FEBS Lett.2002; 521: 180–184.
11.
deBloisD., LombardiD.M., SuE.J., ClowesA.W., SchwartzS.M., GiachelliC.M.Angiotensin II induction of osteopontin expression and DNA replication in rat arteries.Hypertension.1996; 28: 1055–1063.
12.
KiechlS., SchettG., WenningG.Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease.Circulation.2004; 109: 2175–2180.
13.
SoejimaH., IrieA., FukunagaT.Elevated plasma osteopontin levels were associated with osteopontin expression of CD4+ T cells in patients with unstable angina.Circ J.2006; 70: 851–856.
14.
KatoR., MomiyamaY., OhmoriR.High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention.Arterioscler Thromb Vasc Biol.2006; 26: e1–2.
15.
KurataM., OkuraT., WatanabeS., FukuokaT., HigakiJ.Osteopontin and carotid atherosclerosis in patients with essential hypertension.Clin Sci (Lond).2006; 111: 319–324.
16.
GolledgeJ., MullerJ., ShephardN.Association between osteopontin and human abdominal aortic aneurysm.Arterioscler Thromb Vasc Biol.2007; 27: 655–660.
17.
JonoS., IkariY., ShioiA.Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease.Circulation.2002; 106: 1192–1194.
18.
SchoppetM., SattlerA.M., SchaeferJ.R., HerzumM., MaischB., HofbauerL.C.Increased osteoprotegerin serum levels in men with coronary artery disease.J Clin Endocrinol Metab.2003; 88: 1024–1028.
19.
ZieglerS., KudlacekS., LugerA., MinarE.Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease.Atherosclerosis.2005; 182: 175–180.
20.
PennisiP., SignorelliS.S., RiccobeneS.Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels.Osteoporos Int.2004; 15: 389–395.
21.
Report of the expert committee on the diagnosis and classification of diabetes mellitus.Diabetes Care.2003; 26(suppl 1): S5–S20.
22.
TakemotoM., YokoteK., NishimuraM.Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis.Arterioscler Thromb Vasc Biol.2000; 20: 624–628.
23.
OhmoriR., MomiyamaY., TaniguchiH.Plasma osteopontin levels are associated with the presence and extent of coronary artery disease.Atherosclerosis.2003; 170: 333–337.
24.
HirotaS., ImakitaM., KohriK.Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques: a possible association with calcification.Am J Pathol.1993; 143: 1003–1008.
25.
FitzpatrickL.A., SeversonA., EdwardsW.D., IngramR.T.Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis.J Clin Invest.1994; 94: 1597–1604.
26.
BiniA., MannK.G., KudrykB.J., SchoenF.J.Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis.Arterioscler Thromb Vasc Biol.1999; 19: 1852–1861.
27.
SinghK., BalligandJ.L., FischerT.A., SmithT.W., KellyR.A.Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells: Role in regulation of inducible nitric oxide synthase.J Biol Chem.1995; 270: 28471–28478.
28.
IsodaK., KamezawaY., AyaoriM., KusuharaM., TadaN., OhsuzuF.Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions.Circulation.2003; 107: 679–681.
